CARLSBAD, Calif., Dec. 14, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has added three new drugs to its development pipeline, ISIS-APOARx, ISIS-DGAT2Rx and ISIS-FVIIRx. Isis will conduct a conference call tomorrow, December 15, at 12:00 p.m. Eastern Time to provide more detail on these important new drugs.
"2011 has been an extremely successful year for Isis and positions us for an even more successful 2012. Most importantly this year, the European marketing application for Kynamro has been submitted and Genzyme is finalizing the United States NDA submission. We look forward to Genzyme's launch of Kynamro next year, which would be the first systemic antisense drug to reach the market," said Stanley T. Crooke, M.D., Ph.D., Chairman of the Board and Chief Executive Officer at Isis. "Our successes go beyond Kynamro. We have reported positive data demonstrating safety and activity in Phase 1 studies for many of our drugs and are advancing these drugs into later-stage clinical development. The new drugs we added today expand the breadth of both our cardiovascular and metabolic franchises and exemplify our efforts to develop safe and effective drugs that could change the therapeutic landscape in these life-threatening diseases."
ISIS-APOARx reduces apolipoprotein(a) in the liver and is designed to offer a direct approach to reducing Lp(a), an independent risk factor for cardiovascular disease. High levels of Lp(a) are associated with an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke. Lp(a) promotes premature plaque buildup, or atherosclerosis, in arteries. Commonly prescribed lipid-lowering drugs have little or no effect on Lp(a) levels. Patients who are able to control their LDL-C levels, but still have high